Dosage and precautions of neratinib/neratinib

Neratinib/Neratinib is an effective treatment for HER2-positive breast cancer. Its correct use and dosage are crucial to the patient's therapeutic effect. Neratinib/Neratinib is an oral tablet, mainly suitable for adult patients with HER2-positive breast cancer who have received first-line treatment as an adjuvant treatment to reduce the risk of cancer recurrence. For different patients and conditions, the dosage and course of treatment of neratinib may vary, so it must be used under the guidance of a doctor.

Generally speaking, for extended adjuvant treatment of patients with early-stage breast cancer, the recommended dose of neratinib is one tablet (containing 240 mg of neratinib) once daily until disease recurrence or continuous treatment for one year. For patients with advanced or metastatic breast cancer, the recommended dose is also 240 mg (6 tablets) daily, but should be taken daily on days 1 to 21 of a 21-day treatment cycle. Patients also need to take oral capecitabine at a dose of 750 mg/m2 of body surface area twice daily on days 1 to 14 until disease progression or intolerable toxicity occurs. Regarding administration with food, it is recommended that neratinib be taken with food at approximately the same time each day to increase the bioavailability of the drug and reduce possible gastrointestinal discomfort.

This drug is a prescription drug and is strictly prohibited to be used without a prescription. During the treatment period, patients should strictly follow the doctor's medication instructions and should not change the dosage or stop medication at will. If the patient accidentally misses a dose, there is no need to take it again and the patient should continue to take the next dose as originally planned. At the same time, if the patient experiences any discomfort or abnormal reaction, he or she should provide timely feedback to the doctor so that the doctor can adjust the treatment plan according to the specific situation.